Macrophage‐Disguised Manganese Dioxide Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Modulating Inflammatory Microenvironment in Acute Ischemic Stroke
Source abstract
Abstract
Abstract Reperfusion injury is still a major challenge that impedes neuronal survival in ischemic stroke. However, the current clinical treatments are remained on single pathological process, which are due to lack of comprehensive neuroprotective effects. Herein, a macrophage‐disguised honeycomb manganese dioxide (MnO2) nanosphere loaded with fingolimod (FTY) is developed to salvage the ischemic penumbra. In particular, the biomimetic nanoparticles can accumulate actively in the damaged brain via macrophage‐membrane protein‐mediated recognition with cell adhesion molecules that are overexpressed on the damaged vascular endothelium. MnO2 nanosphere can consume excess hydrogen peroxide (H2O2) and convert it into desiderated oxygen (O2), and can be decomposed in acidic lysosome for cargo release, so as to reduce oxidative stress and promote the transition of M1 microglia to M2 type, eventually reversing the proinflammatory microenvironment and reinforcing the survival of damaged neuron. This biomimetic nanomedicine raises new strategy for multitargeted combined treatment of ischemic stroke.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Neuroinflammation and Neurodegeneration Mechanisms · Nanoplatforms for cancer theranostics · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Smart Drug Delivery Ministry of Education State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science Institutes of Brain Science Department of Pharmaceutics School of Pharmacy Fudan University Shanghai 201203 China
Funding
National Natural Science Foundation of China · Program of Shanghai Academic Research Leader
References (49)
Show source-provided references
1. 10.1001/jama.2015.305810.1001/jama.2015.3058 ↗
2. 10.1136/bmj.l698310.1136/bmj.l6983 ↗
3. 10.1016/S0140-6736(16)30962-X10.1016/S0140-6736(16)30962-X ↗
4. 10.1177/0271678X1879816210.1177/0271678X18798162 ↗
5. 10.1161/STROKEAHA.115.01072110.1161/STROKEAHA.115.010721 ↗
6. 10.1161/STROKEAHA.118.02163110.1161/STROKEAHA.118.021631 ↗
7. 10.1038/jcbfm.2012.13910.1038/jcbfm.2012.139 ↗
8. 10.1177/0271678X1560672310.1177/0271678X15606723 ↗
9. 10.1038/nm.239910.1038/nm.2399 ↗
10. 10.1111/j.1747-4949.2012.00839.x10.1111/j.1747-4949.2012.00839.x ↗
11. 10.1097/00004647-200101000-0000210.1097/00004647-200101000-00002 ↗
12. 10.1111/j.1747-4949.2009.00387.x10.1111/j.1747-4949.2009.00387.x ↗
13. 10.3389/fnmol.2020.0002810.3389/fnmol.2020.00028 ↗
14. 10.1159/00006931810.1159/000069318 ↗
15. 10.3389/fneur.2019.0088910.3389/fneur.2019.00889 ↗
16. 10.1161/STROKEAHA.106.46729010.1161/STROKEAHA.106.467290 ↗
17. 10.1097/00004647-199802000-0001110.1097/00004647-199802000-00011 ↗
18. 10.1038/jcbfm.2010.710.1038/jcbfm.2010.7 ↗
19. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
20. 10.1038/nrneurol.2012.9810.1038/nrneurol.2012.98 ↗
21. 10.1038/aps.2016.16210.1038/aps.2016.162 ↗
22. 10.1161/STROKEAHA.112.65965610.1161/STROKEAHA.112.659656 ↗
23. 10.1016/j.pneurobio.2016.01.00510.1016/j.pneurobio.2016.01.005 ↗
24. 10.1002/adma.20180836110.1002/adma.201808361 ↗
25. 10.1002/anie.20180230910.1002/anie.201802309 ↗
26. 10.1161/STROKEAHA.117.01850510.1161/STROKEAHA.117.018505 ↗
27. 10.1186/s12974-019-1538-910.1186/s12974-019-1538-9 ↗
28. 10.1002/adma.20180136210.1002/adma.201801362 ↗
29. 10.1016/j.nbd.2008.08.00510.1016/j.nbd.2008.08.005 ↗
30. 10.1007/s00401-018-1815-110.1007/s00401-018-1815-1 ↗
31. 10.1021/acsnano.9b0180810.1021/acsnano.9b01808 ↗
32. 10.1007/s12017-009-8074-110.1007/s12017-009-8074-1 ↗
33. 10.1152/ajpheart.00588.200410.1152/ajpheart.00588.2004 ↗
34. 10.1016/j.surneu.2005.12.02810.1016/j.surneu.2005.12.028 ↗
35. 10.1016/j.neuint.2006.02.01110.1016/j.neuint.2006.02.011 ↗
36. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
37. 10.1021/acs.nanolett.8b0343910.1021/acs.nanolett.8b03439 ↗
38. 10.1021/acs.nanolett.7b0526310.1021/acs.nanolett.7b05263 ↗
39. 10.1161/STROKEAHA.108.53450310.1161/STROKEAHA.108.534503 ↗
40. 10.1021/jp076113n10.1021/jp076113n ↗
41. 10.2138/am.2006.192510.2138/am.2006.1925 ↗
42. 10.1039/C4CC08172B10.1039/C4CC08172B ↗
43. 10.1089/neu.2000.17.87110.1089/neu.2000.17.871 ↗
44. 10.1021/nn405773r10.1021/nn405773r ↗
45. 10.1002/adfm.20160067610.1002/adfm.201600676 ↗
46. 10.1002/ana.2242610.1002/ana.22426 ↗
47. Joni S. S. · Int. J. Physiol. Pathophysiol. Pharmacol. · 2020 · 12 · 88
48. 10.1161/01.STR.20.1.8410.1161/01.STR.20.1.84 ↗
49. 10.1124/dmd.105.00900110.1124/dmd.105.009001 ↗